Evolution of HIV and HCV coinfected children receiving long-term lopinavir/ritonavir-based antiretroviral therapy

被引：0
|
作者：
Larru, Beatriz [1 ]
Resino, Salvador [1 ,2 ]
Bellon, Jose M. [1 ]
Isabel de Jose Gomez, M. [3 ]
Fortuna, Claudia [4 ]
Munoz-Fernandez, M. Angeles [1 ]
机构：
[1] Hosp Gen Univ Gregorio Maranon, Lab Inmunobiol Mol, Madrid 28007, Spain
[2] Inst Salud Carlos III, Ctr Nacl Microbiol, Madrid, Spain
[3] Hosp Univ La Paz, Serv Inmunopediat, Madrid, Spain
[4] Hosp San Joan de Deu, Serv Inmunopediat, Barcelona, Spain
来源：
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA | 2008年 / 26卷 / 07期
关键词：
HIV; HCV; LPV/r; HAART; children;
D O I：
10.1157/13125640
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
INTRODUCTION. There are few studies investigating the effect of HCV coinfection on HIV-related disease among children. METHODS. We studied 5 HIV/HCV coinfected children receiving an LPV/r-containing HAART regimen. Their evolution was compared with a control group of 72 HIV-infected children. RESULTS. All 5 HIV/HCV-coinfected children achieved sustained immune recovery during the study. Moreover, they showed better viral suppression than the control group. None of the 5 HIV/HCV-coinfected children experienced any adverse effects with the use of LPV/r. CONCLUSION. HIV/HCV coinfection does not reduce the benefits obtained from HAART.
引用
收藏
页码：426 / 429
页数：4
相关论文
共 50 条
  • [1] Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children
    Rudin, Christoph
    Burri, Marcus
    Shen, Yang
    Rode, Richard
    Nadal, David
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (05) : 431 - 437
  • [2] The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
    T. Kredo
    K. Mauff
    L. Workman
    J. S. Van der Walt
    L. Wiesner
    P. J. Smith
    G. Maartens
    K. Cohen
    K. I. Barnes
    BMC Infectious Diseases, 16
  • [3] The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients
    Kredo, T.
    Mauff, K.
    Workman, L.
    Van der Walt, J. S.
    Wiesner, L.
    Smith, P. J.
    Maartens, G.
    Cohen, K.
    Barnes, K. I.
    BMC INFECTIOUS DISEASES, 2016, 16
  • [4] Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir
    Bernal, Enrique
    Masia, Mar
    Padilla, Sergio
    Ramos, J. Manuel
    Martin-Hidalgo, Alberto
    Gutierrez, Felix
    MEDICINA CLINICA, 2007, 129 (07): : 252 - 254
  • [5] Response of HIV positive patients to the long-term salvage therapy by lopinavir/ritonavir
    Václavíková, J
    Machala, L
    Stanková, M
    Linka, M
    Brucková, M
    Vandasová, J
    Konvalinka, J
    JOURNAL OF CLINICAL VIROLOGY, 2005, 33 (04) : 319 - 323
  • [6] Growth in HIV-infected children on long-term antiretroviral therapy
    Feucht, Ute D.
    Van Bruwaene, Lore
    Becker, Piet J.
    Kruger, Mariana
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2016, 21 (05) : 619 - 629
  • [7] HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%
    Shuter, Jonathan
    Sarlo, Julie A.
    Kanmaz, Tina J.
    Rode, Richard A.
    Zingman, Barry S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2007, 45 (01) : 4 - 8
  • [8] Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV-infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
    Naiker, Suhashni
    Connolly, Cathy
    Wiesner, Lubbe
    Kellerman, Tracey
    Reddy, Tarylee
    Harries, Anthony
    McIlleron, Helen
    Lienhardt, Christian
    Pym, Alexander
    BMC PHARMACOLOGY & TOXICOLOGY, 2014, 15
  • [9] Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy
    Suhashni Naiker
    Cathy Connolly
    Lubbe Wiesner
    Tracey Kellerman
    Tarylee Reddy
    Anthony Harries
    Helen McIlleron
    Christian Lienhardt
    Alexander Pym
    BMC Pharmacology and Toxicology, 15
  • [10] The dynamics of HCV-specific antibody responses in HIV/HCV patients on long-term antiretroviral therapy
    Lee, Silvia
    Laiman, Alfred
    French, Martyn A.
    Flexman, James
    Watson, Mark W.
    Price, Patricia
    CLINICAL IMMUNOLOGY, 2017, 179 : 54 - 63
12345